10-Q quarterly report · filed Nov 12, 2026

CODEXIS, INC. (CDXS) Q3 2026 10-Q Quarterly Report

Short answer

CODEXIS, INC. (CDXS) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $19M (up 124.0% year over year) with net income of −$8M.

Q3 2026 key financials · XBRL

Revenue
$19M
+124.0% YoY · +29.2% QoQ
Net income
−$8M
+58.6% YoY · +32.3% QoQ
Operating margin
-38.6%
EPS (diluted)
−$0.07
+68.2% YoY · +46.2% QoQ

Source: XBRL data from the CODEXIS, INC. (CDXS) Q3 2026 10-Q on SEC EDGAR. USD.

CODEXIS, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $19.3M, up $10.7M YoY from $8.6M
  • Product revenue $15.7M, up $8.9M, driven by $8.4M higher commercial pharmaceutical enzyme sales
  • Product gross margin 74% vs 64% YoY, reflecting a shift toward more profitable products
  • Operating loss $7.4M vs $18.9M YoY, net loss $8.1M vs $19.6M
  • Cash $29.2M vs $50.8M, operating cash use $30.6M, July equity offering net proceeds $24.9M

Risk Factors

  • Newly highlighted compliance risk: U.S. BIOSECURE Act enacted December 2025 could restrict counterparties deemed biotechnology companies of concern
  • Most material operational update: ECO GMP Manufacturing Center retrofit begins Q4 2026, with potential permitting delays and cost overruns
  • Regulatory risk: FDA could reject the Company’s FDCA exemption, requiring cGMP compliance and potentially halting product distribution
  • Market risk: customers contributed 48% of nine-month revenue, increasing exposure to customer losses or reduced purchases
  • Financial risk: Trinity LSA includes $7.5 million available through December 15, 2027 and liquidity covenant tied to $400.0 million market capitalization

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other CODEXIS, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.